Author/Authors :
Pérez-Cebrián, Manuela Pharmacy Service - University Hospital La Fe - Valencia, Spain , Morales Suárez-Varela, María M Unit of Public Health and Environmental Care - Department of Preventive Medicine - University of Valencia, Spain - CIBER of Epidemiology and Public Health (CIBERESP) - Madrid, Spain - Center for Public Health Research (CSISP) - Valencia, Spain , Font-Noguera, Isabel Pharmacy Service - University Hospital La Fe - Valencia, Spain , Monte-Boquet, Emilio Pharmacy Service - University Hospital La Fe - Valencia, Spain , Poveda-Andrés, Jose Luís Pharmacy Service - University Hospital La Fe - Valencia, Spain , María Martín-Moreno, Jose Unit of Public Health and Environmental Care - Department of Preventive Medicine - University of Valencia, Spain , Rubio-López, Nuria Unit of Public Health and Environmental Care - Department of Preventive Medicine - University of Valencia, Spain - CIBER of Epidemiology and Public Health (CIBERESP) - Madrid, Spain - Center for Public Health Research (CSISP) - Valencia, Spain , Ruiz-Rojo, Elias Conselleria de Sanidad - Valencia, Spain - CIBER of Epidemiology and Public Health (CIBERESP) - Madrid, Spain , Llopis-González, Agustín Unit of Public Health and Environmental Care - Department of Preventive Medicine - University of Valencia, Spain - CIBER of Epidemiology and Public Health (CIBERESP) - Madrid, Spain - Center for Public Health Research (CSISP) - Valencia, Spain
Abstract :
Indications for linezolid use are nosocomial or community-acquired pneumonia and
skin infections or soft tissue infection caused by gram-positive microorganisms, but new recommendations may emerge. It is important to balance benefits with risks because severe adverse events have been described in patients taking linezolid treatment. Accordingly, we evaluated the suitability of linezolid prescription according to approval of indication by evaluating the presence of drug-related problems (DRP) in a University hospital. DRP were identified in 36 patients (50.0%). In most cases, they were related to known or established indications (15 patients, 20.8%), to safety (5 patients, 6.9%), and to both in others (16 patients, 22.2%). No DRP were recorded, which modified linezolid efficacy. DRP were significantly higher in the patients treated by an approved indication in Spain (63.3%) than in those treated by an unapproved indication in Spain (28.6%). We concluded that new studies about extending
linezolid indications may be necessary.
Keywords :
Approval of indications , Drug-related problems , Drug safety evaluation , Linezolid prescription , University hospital
